FAQ

AgeViva™ is a Swedish dietary supplement based on a unique yeast culture from Saccharomyces cerevisiae, treated with electromagnetic millimeter waves. The product is patent-pending and developed in collaboration with international researchers.

AgeViva is based on a patented biotechnological process that alters the properties of yeast cells. In studies, the product has shown effects on cognitive function, the immune system, muscles, bone health, autophagy, and lifespan in model organisms.

Yes. Several toxicity tests have been conducted under the supervision of Professor Rita Businaro. In addition, the product is GRAS-documented for its U.S. FDA launch, confirming its safety profile.

Yes. Studies have been conducted since 2007, including at Uppsala University and Sapienza University in Rome. The results show a significant effect compared to placebo. In scientific publications, the product is referred to as Milmed.

Studies have shown that AgeViva may contribute to:

• Cognitive function & mental performance

• Normal functioning of the immune system

• Maintenance of normal muscles and bones

• Protection of cells against oxidative stress

• Enhanced autophagy (the cells' recycling system)

• Extended lifespan in studies with the model organism C. elegans C. elegans

The yeast is produced in Sweden by Orkla Group, Jästbolaget, the largest yeast producer in Scandinavia. Sales and development are conducted through Longevience AB, a subsidiary of Milmed Unico AB. Longevience AB, a subsidiary of Milmed Unico AB

The research is led by Professor Trevor Archer in collaboration with Professor Rita Businaro at Sapienza University in Rome. In vitro and in vivo studies have been ongoing since 2007.

AgeViva™ has already been launched in Sweden and is available for purchase. In 2025, further expansion is planned into several European countries, including Germany, Austria, France, Italy, and the United Kingdom.